{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:13:47Z","timestamp":1792088027020,"version":"4.4.0"},"reference-count":47,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T00:00:00Z","timestamp":1736121600000},"content-version":"unspecified","delay-in-days":5,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,12,6]]},"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Small cell lung cancer (SCLC) is an aggressive form of neuroendocrine neoplasm known for its striking initial response to treatment, followed by fast relapse and refractoriness in response to additional lines of therapy. New advances in immunotherapy are paving the way for more effective treatment strategies and have promising results with early clinical trial data. While SCLC rarely harbors actionable mutations, the receptor DLL3 is extensively present in SCLC, making it a potential target for immunotherapy. Three emerging therapeutic options include bispecific T cell engagers targeting DLL3, chimeric antigen receptor T cells (CAR-T cells), and antibody\u2013drug conjugates. Several phase II and phase III clinical trials for bispecific T cell engagers show promise. Additionally, the first CAR-T cell trials in humans for SCLC are currently underway.<\/jats:p>","DOI":"10.1136\/jitc-2024-009667","type":"journal-article","created":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T21:00:21Z","timestamp":1736197221000},"page":"e009667","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":32,"title":["New developments in immunotherapy for SCLC"],"prefix":"10.1136","volume":"13","clinical-trial-number":[{"clinical-trial-number":"nct05882058","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05652686","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05680922","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct05680922","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Tsering","family":"Dolkar","sequence":"first","affiliation":[{"name":"Hospital Medicine, University of Kentucky, Lexington, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Gates","sequence":"additional","affiliation":[{"name":"Hematology - Oncology, University of Kentucky, Lexington, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhonglin","family":"Hao","sequence":"additional","affiliation":[{"name":"Medical Oncollogy, University of Kentucky, Lexington, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reinhold","family":"Munker","sequence":"additional","affiliation":[{"name":"University of Kentucky, Lexington, Kentucky, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,1,6]]},"reference":[{"key":"2025100312165085000_13.1.e009667.1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.lungcan.2021.04.013","article-title":"Platinum-doublet chemotherapy as second-line treatment for relapsed patients with small-cell lung cancer: A systematic review and meta-analysis","volume":"156","author":"Horiuchi","year":"2021","journal-title":"Lung Cancer (Auckl)"},{"key":"2025100312165085000_13.1.e009667.2","unstructured":"National comprehensive cancer network (v. 2.2025). 2025. Available: https:\/\/www.nccn.org\/"},{"key":"2025100312165085000_13.1.e009667.3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30068-1"},{"key":"2025100312165085000_13.1.e009667.4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2025100312165085000_13.1.e009667.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2016.06.081"},{"key":"2025100312165085000_13.1.e009667.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2020.12.014"},{"key":"2025100312165085000_13.1.e009667.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.12.004"},{"key":"2025100312165085000_13.1.e009667.8","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1001\/jamaoncol.2023.4025","article-title":"Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial","volume":"9","author":"Takahashi","year":"2023","journal-title":"JAMA Oncol"},{"key":"2025100312165085000_13.1.e009667.9","doi-asserted-by":"publisher","DOI":"10.1101\/gad.349359.122"},{"key":"2025100312165085000_13.1.e009667.10","doi-asserted-by":"publisher","DOI":"10.1053\/bbmt.2002.v8.pm12064365"},{"key":"2025100312165085000_13.1.e009667.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"2025100312165085000_13.1.e009667.12","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"2025100312165085000_13.1.e009667.13","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.cllc.2021.09.003","article-title":"Current Strategies for Extensive Stage Small Cell Lung Cancer Beyond First-line Therapy","volume":"23","author":"Hao","year":"2022","journal-title":"Clin Lung Cancer"},{"key":"2025100312165085000_13.1.e009667.14","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.01363"},{"key":"2025100312165085000_13.1.e009667.15","unstructured":"Pennell NA , Rugo H , Barata PC , eds. In: The ASCO Educational Book 2023. Chicago: American Society of Clinical Oncology, 2024."},{"key":"2025100312165085000_13.1.e009667.16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-20-0913"},{"key":"2025100312165085000_13.1.e009667.17","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1056\/NEJMoa2404873","article-title":"Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer","volume":"391","author":"Cheng","year":"2024","journal-title":"N Engl J Med"},{"key":"2025100312165085000_13.1.e009667.18","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13997"},{"key":"2025100312165085000_13.1.e009667.19","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.lungcan.2020.07.026","article-title":"International real-world study of DLL3 expression in patients with small cell lung cancer","volume":"147","author":"Rojo","year":"2020","journal-title":"Lung Cancer (Auckl)"},{"key":"2025100312165085000_13.1.e009667.20","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1007\/s11523-023-01008-x","article-title":"Systematic Literature Review of the Prevalence and Prognostic Value of Delta-Like Ligand 3 Protein Expression in Small Cell Lung Cancer","volume":"18","author":"Bylsma","year":"2023","journal-title":"Target Oncol"},{"key":"2025100312165085000_13.1.e009667.21","article-title":"Tarlatamab for Large Cell Neuroendocrine Carcinoma in a Young Adult: A Case Report","volume":"5","author":"Patel","year":"2024","journal-title":"JTO Clin Res Rep"},{"key":"2025100312165085000_13.1.e009667.22","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1038\/s41416-023-02427-3","article-title":"Tumor microenvironment-mediated immune profiles and efficacy of anti-PD-L1 antibody plus chemotherapy stratified by DLL3 expression in small-cell lung cancer","volume":"129","author":"Shirasawa","year":"2023","journal-title":"Br J Cancer"},{"key":"2025100312165085000_13.1.e009667.23","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1158\/1078-0432.CCR-21-1533","article-title":"Radioimmunotherapy Targeting Delta-like Ligand 3 in Small Cell Lung Cancer Exhibits Antitumor Efficacy with Low Toxicity","volume":"28","author":"Tully","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025100312165085000_13.1.e009667.24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005187","article-title":"GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma","volume":"10","author":"Gargett","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100312165085000_13.1.e009667.25","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.01000","article-title":"Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy","volume":"10","author":"Nazha","year":"2020","journal-title":"Front Oncol"},{"key":"2025100312165085000_13.1.e009667.26","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003897","article-title":"Targeting disialoganglioside GD2 with chimeric antigen receptor-redirected T cells in lung cancer","volume":"10","author":"Reppel","year":"2022","journal-title":"J Immunother Cancer"},{"key":"2025100312165085000_13.1.e009667.27","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-09-306449"},{"key":"2025100312165085000_13.1.e009667.28","doi-asserted-by":"crossref","DOI":"10.1186\/s40364-021-00294-9","article-title":"The landscape of bispecific T cell engager in cancer treatment","volume":"9","author":"Zhou","year":"2021","journal-title":"Biomark Res"},{"key":"2025100312165085000_13.1.e009667.29","doi-asserted-by":"crossref","DOI":"10.1186\/s13045-023-01464-y","article-title":"Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer","volume":"16","author":"Rudin","year":"2023","journal-title":"J Hematol Oncol"},{"key":"2025100312165085000_13.1.e009667.30","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","article-title":"Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer","volume":"389","author":"Ahn","year":"2023","journal-title":"N Engl J Med"},{"key":"2025100312165085000_13.1.e009667.31","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1200\/JCO.22.02823","article-title":"Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study","volume":"41","author":"Paz-Ares","year":"2023","journal-title":"J Clin Oncol"},{"key":"2025100312165085000_13.1.e009667.32","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"2025100312165085000_13.1.e009667.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"2025100312165085000_13.1.e009667.34","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000785","article-title":"Combined DLL3-targeted bispecific antibody with PD-1 inhibition is efficient to suppress small cell lung cancer growth","volume":"8","author":"Chen","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2025100312165085000_13.1.e009667.35","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1158\/2326-6066.CIR-23-0638","article-title":"Engineering CD3\/CD137 Dual Specificity into a DLL3-Targeted T-Cell Engager Enhances T-Cell Infiltration and Efficacy against Small-Cell Lung Cancer","volume":"12","author":"Mikami","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"2025100312165085000_13.1.e009667.36","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1133"},{"key":"2025100312165085000_13.1.e009667.37","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1016\/j.jtho.2021.07.012","article-title":"All That Glitters Is Not Gold: The Story of Rovalpituzumab Tesirine in SCLC","volume":"16","author":"Uprety","year":"2021","journal-title":"J Thorac Oncol"},{"key":"2025100312165085000_13.1.e009667.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00754-1"},{"key":"2025100312165085000_13.1.e009667.39","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/1078-0432.CCR-22-2293","article-title":"Allogeneic CAR T Cells Targeting DLL3 Are Efficacious and Safe in Preclinical Models of Small Cell Lung Cancer","volume":"29","author":"Zhang","year":"2023","journal-title":"Clin Cancer Res"},{"key":"2025100312165085000_13.1.e009667.40","doi-asserted-by":"crossref","DOI":"10.1172\/JCI166028","article-title":"IL-18-secreting CAR T cells targeting DLL3 are highly effective in small cell lung cancer models","volume":"133","author":"Jaspers","year":"2023","journal-title":"J Clin Invest"},{"key":"2025100312165085000_13.1.e009667.41","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/JLB.5MA0122-467R","article-title":"CAR NK-92 cells targeting DLL3 kill effectively small cell lung cancer cells in vitro and in vivo","volume":"112","author":"Liu","year":"2022","journal-title":"J Leukoc Biol"},{"key":"2025100312165085000_13.1.e009667.42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.33.3716"},{"key":"2025100312165085000_13.1.e009667.43","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","article-title":"CAR T cell killing requires the IFN\u03b3R pathway in solid but not liquid tumours","volume":"604","author":"Larson","year":"2022","journal-title":"Nature New Biol"},{"key":"2025100312165085000_13.1.e009667.44","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1158\/0008-5472.CAN-22-2245","article-title":"Systematic Interrogation of Tumor Cell Resistance to Chimeric Antigen Receptor T-cell Therapy in Pancreatic Cancer","volume":"83","author":"Hagel","year":"2023","journal-title":"Cancer Res"},{"key":"2025100312165085000_13.1.e009667.45","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02612-0"},{"key":"2025100312165085000_13.1.e009667.46","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1118610","article-title":"Immune checkpoint inhibitors and Chimeric Antigen Receptor (CAR)-T cell therapy: Potential treatment options against Testicular Germ Cell Tumors","volume":"14","author":"Schepisi","year":"2023","journal-title":"Front Immunol"},{"key":"2025100312165085000_13.1.e009667.47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.879608","article-title":"Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy","volume":"13","author":"Sterner","year":"2022","journal-title":"Front Immunol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2024-009667","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T19:17:00Z","timestamp":1759519020000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2024-009667"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1,6]]},"published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1136\/jitc-2024-009667"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2024-009667","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]}}}